NXP800 is an orally bioavailable small molecule activator of the GCN2 kinase.
GCN2 phosphorylates the eukaryotic translation initiation factor 2 (eIF2), which results in lower bulk protein synthesis and in induction of preferential translation of stress-adaptive gene transcripts, such as that encoding the ATF4 transcription regulator. Chronic activation of GCN2 by NXP800 leads to cancer cell death.
